Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy

AIDS

Volumn 15, Issue 6, 2001, Pages 665-673

  Ngo Giang Huong, Nicole ^a   Deveau, Christiane ^b   Da Silva, Isabelle ^a   Pellegrin, Isabelle ^c   Venet, Alain ^d   Harzic, Martine ^e   Sinet, Martine ^d   Delfraissy, Jean François ^b   Meyer, Laurence ^b   Goujard, Cécile ^b   Rouzioux, Christine ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

^c HÔPITAL PELLEGRIN   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e Service de Microbiologie   (France)

Author keywords

Highly active antiretroviral therapy; Primary HIV 1 infection; Proviral HIV 1 DNA

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PROSPECTIVE STUDIES; PROVIRUSES; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 0035853422     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200104130-00001     Document Type: Article

References (35)

1. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
2. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection
3. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
4. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia
5. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
6. Risk of developing AIDS after primary acute HIV-1 infection
7. Influence of neurologic manifestations of primary human immunodeficincy virus infection on disease progression
8. Plasma viremia in macaques infected with simian immunodeficiency virus: Plasma viral load early in infection predicts survival
9. Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile
10. Circulating HIV-1 infected cell burden from postseroconversion to AIDS: Importance of postseroconversion viral load on disease course
11. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
12. Natural history of serum HIV-RNA levels in 330 patients with a known date of infection
13. Weak anti-HIV CD8+ T-cell effector activity in HIV primary infection
14. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment
15. PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells
16. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
17. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
18. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
19. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection
20. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
21. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
22. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
23. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
24. Constant mean viral copy number per infected cell in tissues of high, low or undetectable plasma HIV RNA
25. HIV-1 replication in patients with undetectable plasma virus receiving HAART
26. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy
27. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
28. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
29. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
30. Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy
31. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: Implications for timing of antiretroviral therapy
32. Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection
33. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
34. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy
35. CCR5 Δ32 deletion and response to HAART in HIV-1-infected patients